Report an error

Spotted something inaccurate in “Pembrolizumab plus Belzutifan Improves Disease-Free Survival After Surgery in High-Risk Kidney Cancer”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.